How ciprofol behaves and affects older adults having limb surgery under general anesthesia
Official title: Population Pharmacokinetic/Pharmacodynamic Modeling of Ciprofol in Elderly Patients Undergoing Orthopedic Limb Surgery
Run by Shanghai Geriatric Medical Center · NCT07301242 · Data updated 2026-11-12
This study tests whether ciprofol provides safe and effective anesthesia for older adults having elective limb surgery by measuring drug levels and clinical responses.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Shanghai Geriatric Medical Center Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | October 28, 2025 |
| Main results expected | November 2026 |
| Study ends | December 2026 |
| Registry record updated | December 24, 2025 |
| Trial ID | NCT07301242 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 65 or older with BMI 18–30 kg/m², ASA physical status I–III, scheduled for elective orthopedic limb surgery lasting more than 30 minutes, and able to give informed consent.
✕Probably not a fit
Patients younger than 65, those not receiving ciprofol, emergency surgery cases, or people with significant preoperative cognitive impairment or contraindications to ciprofol are unlikely to benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, prospective observational project enrolling patients aged 65 and older who receive ciprofol as part of routine general anesthesia for elective orthopedic limb surgery. Participants will provide timed blood samples during and after surgery while researchers record vital signs, anesthesia dosing, recovery scores (such as the Aldrete score), and signs of postoperative delirium. Collected data will be used to build and validate a population pharmacokinetic/pharmacodynamic (PK/PD) model tailored to elderly orthopedic patients. The validated model aims to support target-controlled infusion (TCI) systems for more individualized intraoperative dosing.
Why it matters
Potential benefit: If successful, the generated PK/PD model could help clinicians use TCI to tailor ciprofol dosing in elderly patients and reduce risks of over- or under-dosing.
How similar studies have gone: Ciprofol has shown promising safety and efficacy in earlier trials mostly involving younger or healthier populations, but PK/PD models for elderly orthopedic patients remain limited, so applying these methods in this group is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥65 years; * BMI: 18-30 kg/m²; * ASA physical status classification I-III; * Scheduled for elective orthopedic limb surgery under general anesthesia; * Expected duration of surgery \>30 minutes; * Willing to participate and able to provide written informed consent. Exclusion Criteria: * Known allergy to ciprofol or related medications, or any contraindication to their use; * Preoperative cognitive impairment; * History of severe cerebrovascular disease or related complications; * History of neuromuscular system diseases or psychiatric disorders; * History of sedative medication use; * History of alcohol abuse or substance use disorder; * Bradycardia (heart rate \<60 beats per minute); * Hypotension (mean arterial pressure \<55 mmHg); * QT interval prolongation; * Uncooperative or unable to communicate effectively.
Where it's running
-
Shanghai Geriatric Medical Center
Shanghai, China Recruiting
Study contacts
- Principal investigator: Xue Zhang — Shanghai Geriatric Medical Center
- Study coordinator: Xue Zhang
- Email: zx02190554@126.com
- Phone: 02164175590
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Collarless Actis hip stem for cementless hip replacement in Asian patients
This study tests how well a collarless Actis hip stem works in adults undergoing primary hip replacement, focusing on outcomes over five years in an East Asian population.
-
Bone marrow injection at the femoral neck fracture site in young adults with intracapsular hip fractures
This study tests whether injecting the patient’s own bone marrow into a femoral neck fracture helps it heal faster and reduces avascular necrosis in adults aged 18–55 with certain fracture types.
-
Tipmed™ Primary Hip Prosthesis: 24-Month Post-Market Follow-Up in Adults
This PMCF study tests the safety and 24‑month performance of the Tipmed hip prosthesis in adults undergoing primary hip replacement.
-
Predicting mobility and daily living independence after a hip fracture
Try a machine‑learning tool to predict three‑month mobility and ability to perform everyday activities for adults after a hip fracture.
-
Sacral ESPB versus PENG nerve block for pain after hip hemiarthroplasty
We will see if a sacral erector spinae plane (S-ESPB) block or a pericapsular nerve group (PENG) block gives better pain relief for adults 50–90 having hip hemiarthroplasty for a femoral neck fracture.
-
Fixation versus arthroplasty for faster recovery after minimally displaced femoral neck fractures (FASTER-HIP)
This trial will test whether replacing the hip (arthroplasty) instead of fixing the bone (internal fixation) helps people aged 60 and older with minimally displaced femoral neck fractures recover faster, stay alive and walking, and spend more days at home over the first year.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.